20 articles
A new perspective outlines how stem cells, bioprinted organs, and cross-species genes could replace — not just repair — aging biology.
Beijing's 301 Hospital begins recruiting adults 50+ for the world's largest stem cell antiaging clinical trial using an already-approved therapy.
Chinese researchers developed a breakthrough method to mass-produce powerful immune cells that hunt and destroy cancer tumors.
CellProthera's ProtheraCytes targets heart repair post-myocardial infarction, aiming to prevent heart failure before damage becomes irreversible.
Heartseed's iPSC-derived heart cell therapy enters Phase I/II trial for dilated cardiomyopathy, with first patient data cleared by safety board.
Astellas reports encouraging early-stage results for a stem cell-derived treatment targeting age-related eye disease, though data remains limited.
Engineered heart muscle patches from stem cells thickened weakened heart walls and improved pumping ability in a small human trial.
XellSmart's XS411 transplants lab-grown dopamine neurons into Parkinson's brains, showing early motor gains and no adverse events.
A naturally occurring stem cell type called Muse cells shows early promise in homing to damaged tissue, differentiating widely, and avoiding immune rejection.
A rare stress-resilient cell type may solve the biggest failure in stem cell therapy: most injected cells never reach damaged tissue.
Aspen Neuroscience's stem cell therapy restored dopamine neurons in Parkinson's patients, adding ~2 hours of controlled movement daily.
Mesoblast licenses CAR technology to make its stem cell therapies smarter at finding inflamed tissue, targeting IBD and autoimmune disease.
Chinese biotech begins multicenter trial of stem cell therapy showing promising early results for Parkinson's motor symptoms and quality of life.
A rare stress-enduring stem cell subpopulation called Muse cells could solve regenerative medicine's biggest failures and slow tissue aging.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
RBI's Wnt-activated stem cells injected directly into the brain show early promise reducing tau and amyloid markers in Phase 1.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
Five beta thalassemia patients no longer need regular blood transfusions after Chinese gene therapy treatment.
QT-019B targets two cancer markers at once using off-the-shelf engineered T cells, now holding every major FDA expedited development status.
Aspen's personalized iPSC cell therapy shows meaningful motor and quality-of-life gains in first 8 Parkinson's patients at 12 months.
